Peregrine Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Peregrine Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.63M	Buy	+25,790	New	+$8.16M	0.28%	111

Other funds holding PRAX

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

EFA

Englebert Financial Advisers Allentown, Pennsylvania $102M AUM

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Peregrine Capital Management's PRAX Position: Q2 2026 in Review

Peregrine Capital Management opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 25,790 shares worth $8.63M. The stake represents 0.28% of the portfolio and ranks #111 among its holdings.

22 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Peregrine Capital Management held 25,790 shares of Praxis Precision Medicines worth $8.63M as of Q2 2026.
Praxis Precision Medicines was a new Peregrine Capital Management position in Q2 2026.
Praxis Precision Medicines made up 0.28% of Peregrine Capital Management's portfolio in Q2 2026, its #111 holding.
22 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.